Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Income (2016 - 2025)

Historic Net Income for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $17.3 million.

  • Amicus Therapeutics' Net Income rose 35718.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 8656.87%. This contributed to the annual value of -$56.1 million for FY2024, which is 6298.69% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Net Income stood at $17.3 million, which was up 35718.53% from -$24.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Net Income registered a high of $17.3 million during Q3 2025, and its lowest value of -$85.3 million during Q1 2022.
  • Over the past 5 years, Amicus Therapeutics' median Net Income value was -$43.2 million (recorded in 2023), while the average stood at -$38.1 million.
  • Over the last 5 years, Amicus Therapeutics' Net Income had its largest YoY gain of 35718.53% in 2025, and its largest YoY loss of 5557.11% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Net Income (Quarter) stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then surged by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then rose by 17.42% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, -$24.4 million for Q2 2025, and -$21.7 million during Q1 2025.